Literature DB >> 21615147

Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.

Mansour Debdab1, François Carreaux, Steven Renault, Meera Soundararajan, Oleg Fedorov, Panagis Filippakopoulos, Olivier Lozach, Lucie Babault, Tania Tahtouh, Blandine Baratte, Yasushi Ogawa, Masatoshi Hagiwara, Andreas Eisenreich, Ursula Rauch, Stefan Knapp, Laurent Meijer, Jean-Pierre Bazureau.   

Abstract

We here report on the synthesis, optimization, and biological characterization of leucettines, a family of kinase inhibitors derived from the marine sponge leucettamine B. Stepwise synthesis of analogues starting from the natural structure, guided by activity testing on eight purified kinases, led to highly potent inhibitors of CLKs and DYRKs, two families of kinases involved in alternative pre-mRNA splicing and Alzheimer's disease/Down syndrome. Leucettine L41 was cocrystallized with CLK3. It interacts with key residues located within the ATP-binding pocket of the kinase. Leucettine L41 inhibits the phosphorylation of serine/arginine-rich proteins (SRp), a family of proteins regulating pre-RNA splicing. Indeed leucettine L41 was demonstrated to modulate alternative pre-mRNA splicing, in a cell-based reporting system. Leucettines should be further explored as pharmacological tools to study and modulate pre-RNA splicing. Leucettines may also be investigated as potential therapeutic drugs in Alzheimer's disease (AD) and in diseases involving abnormal pre-mRNA splicing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615147     DOI: 10.1021/jm200274d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.

Authors:  Julien Debray; Simon Bonte; Olivier Lozach; Laurent Meijer; Martine Demeunynck
Journal:  Mol Divers       Date:  2012-09-19       Impact factor: 2.943

Review 2.  The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.

Authors:  James A DeCaprio; Anette Duensing
Journal:  Curr Opin Oncol       Date:  2014-07       Impact factor: 3.645

Review 3.  Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.

Authors:  Jacqueline Olender; Norman H Lee
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases.

Authors:  Qifang Xu; Kimberly L Malecka; Lauren Fink; E Joseph Jordan; Erin Duffy; Samuel Kolander; Jeffrey R Peterson; Roland L Dunbrack
Journal:  Sci Signal       Date:  2015-12-01       Impact factor: 8.192

5.  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Authors:  C Delehouzé; K Godl; N Loaëc; C Bruyère; N Desban; N Oumata; H Galons; T I Roumeliotis; E G Giannopoulou; J Grenet; D Twitchell; J Lahti; N Mouchet; M-D Galibert; S D Garbis; L Meijer
Journal:  Oncogene       Date:  2013-12-09       Impact factor: 9.867

Review 6.  More than a messenger: Alternative splicing as a therapeutic target.

Authors:  A J Black; J R Gamarra; J Giudice
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-02       Impact factor: 4.490

7.  New 5-ylidene rhodanine derivatives based on the dispacamide A model.

Authors:  Solene Guiheneuf; Ludovic Paquin; François Carreaux; Emilie Durieu; Thierry Roisnel; Laurent Meijer; Jean-Pierre Bazureau
Journal:  Mol Divers       Date:  2014-03-02       Impact factor: 2.943

Review 8.  Recent progress in neuroactive marine natural products.

Authors:  Ryuichi Sakai; Geoffrey T Swanson
Journal:  Nat Prod Rep       Date:  2014-01-17       Impact factor: 13.423

9.  cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.

Authors:  Xavier Fant; Emilie Durieu; Gaëtan Chicanne; Bernard Payrastre; Diego Sbrissa; Assia Shisheva; Emmanuelle Limanton; François Carreaux; Jean-Pierre Bazureau; Laurent Meijer
Journal:  Mol Pharmacol       Date:  2013-12-23       Impact factor: 4.436

Review 10.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.